NCT05933538View on ClinicalTrials.gov

Effectiveness of Cariprazine Monotherapy for Treatment of Major Depressive Disorder

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

August 31, 2024

Primary Completion Date

August 31, 2030

Study Completion Date

December 31, 2030

Conditions
Depressive Disorder, Major
Interventions
DRUG

Cariprazine

The starting dose is 1.5 mg once daily which will be titrated according to the treating psychiatrist who assessing the response with maximum dose of 4.5mg. The dose to be escalated on 2 weekly interval.

COMBINATION_PRODUCT

Treatment as usual

Participants in this will receive either antidepressants including SSRI, SNRI or TCA or for psychotherapy alone or a combination of psychotherapy and antidepressants.

All Listed Sponsors
lead

Sultan Qaboos University

OTHER

NCT05933538 - Effectiveness of Cariprazine Monotherapy for Treatment of Major Depressive Disorder | Biotech Hunter | Biotech Hunter